Format

Send to

Choose Destination
See comment in PubMed Commons below
Iran J Immunol. 2012 Dec;9(4):215-25. doi: IJIv9i4A1.

An endogenous immune adjuvant released by necrotic cells for enhancement of DNA vaccine potency.

Author information

1
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran, e-mail: Bamdad_T@modares.ac.ir.

Abstract

BACKGROUND:

Improving vaccine potency in the induction of a strong cell-mediated cytotoxicity can enhance the efficacy of vaccines. Necrotic cells and the supernatant of necrotic tumor cells are attractive adjuvants, on account of their ability to recruit antigen-presenting cells to the site of antigen synthesis as well as its ability to stimulate the maturation of dendritic cells.

OBJECTIVE:

To evaluate the utility of supernatant of necrotic tumor cells as a DNA vaccine adjuvant in a murine model.

METHOD:

The supernatant of EL4 necrotic cells was co-administered with a DNA vaccine expressing the glycoprotein B of Herpes simplex virus-1 as an antigen model under the control of Cytomegalovirus promoter. C57BL/6 mice were vaccinated three times at two weeks intervals with glycoprotein B DNA vaccine and supernatant of necrotic EL4 cells. Five days after the last immunization, cell cytotoxicity, IFN-γ and IL-4 were evaluated.

RESULTS:

The obtained data showed that the production of IFN-γ from the splenocytes after antigenic stimulation in the presence of the supernatant of necrotic EL4 cells was significantly higher than the other groups (p<0.002). The flow cytometry results showed a significant increase in the apoptosis/necrosis of EL4 cells in the mice immunized with DNA vaccine and supernatant of necrotic EL4 cells comparing to the other groups (p<0.001).

CONCLUSION:

The supernatant of necrotic cells contains adjuvant properties that can be considered as a candidate for tumor vaccination.

PMID:
23268287
DOI:
IJIv9i4A1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center